PT3527210T - Composição combinada que compreende um composto benzo-heterocíclico e um modulador da via dos recetores de androgénio e usos da mesma - Google Patents
Composição combinada que compreende um composto benzo-heterocíclico e um modulador da via dos recetores de androgénio e usos da mesmaInfo
- Publication number
- PT3527210T PT3527210T PT178811717T PT17881171T PT3527210T PT 3527210 T PT3527210 T PT 3527210T PT 178811717 T PT178811717 T PT 178811717T PT 17881171 T PT17881171 T PT 17881171T PT 3527210 T PT3527210 T PT 3527210T
- Authority
- PT
- Portugal
- Prior art keywords
- composition
- application
- treatment method
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611170723 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3527210T true PT3527210T (pt) | 2021-08-11 |
Family
ID=62558044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT178811717T PT3527210T (pt) | 2016-12-16 | 2017-12-15 | Composição combinada que compreende um composto benzo-heterocíclico e um modulador da via dos recetores de androgénio e usos da mesma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10933059B2 (pt) |
| EP (1) | EP3527210B1 (pt) |
| JP (1) | JP7048106B2 (pt) |
| KR (2) | KR102368555B1 (pt) |
| CN (1) | CN110049765B (pt) |
| AU (1) | AU2017376704B2 (pt) |
| BR (1) | BR112019010559B1 (pt) |
| CA (1) | CA3046869C (pt) |
| DK (1) | DK3527210T3 (pt) |
| ES (1) | ES2884064T3 (pt) |
| PL (1) | PL3527210T3 (pt) |
| PT (1) | PT3527210T (pt) |
| RU (1) | RU2731535C1 (pt) |
| WO (1) | WO2018108147A1 (pt) |
| ZA (1) | ZA201904328B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2624949C (en) | 1996-07-24 | 2011-02-15 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| PL2444085T3 (pl) | 2005-05-13 | 2015-07-31 | Univ California | Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka |
| PL2428513T3 (pl) | 2006-09-26 | 2017-10-31 | Celgene Corp | Pochodne 5-podstawionego chinazolinonu jako środki przeciwnowotworowe |
| CN101679380A (zh) | 2007-03-20 | 2010-03-24 | 细胞基因公司 | 4’-o-取代的异吲哚啉衍生物和包含它的组合物及使用方法 |
| AU2009314568B2 (en) | 2008-11-14 | 2016-01-21 | Concert Pharmaceuticals Inc. | Substituted dioxopiperidinyl phthalimide derivaties |
| US9045453B2 (en) | 2008-11-14 | 2015-06-02 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| EP4289838A3 (en) | 2010-02-11 | 2024-03-13 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| LT2785349T (lt) * | 2011-11-30 | 2019-12-10 | Astrazeneca Ab | Kombinuotas vėžio gydymas |
| EA029563B1 (ru) | 2012-07-27 | 2018-04-30 | Арагон Фармасьютикалз, Инк. | Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор |
| WO2014039421A1 (en) | 2012-09-04 | 2014-03-13 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| WO2014110558A1 (en) | 2013-01-14 | 2014-07-17 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| JP6100439B2 (ja) * | 2013-05-10 | 2017-03-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節薬のエステル誘導体およびそれらの使用のための方法 |
| CN105566290B (zh) * | 2014-10-30 | 2020-05-22 | 康朴生物医药技术（上海）有限公司 | 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用 |
| PL3357513T3 (pl) * | 2015-09-29 | 2024-04-02 | Kangpu Biopharmaceuticals, Ltd. | Kompozycja farmaceutyczna i jej zastosowanie |
| KR102125661B1 (ko) | 2017-02-13 | 2020-06-22 | 강푸 바이오파마슈티칼즈 리미티드 | 전립선암 치료용 조합, 약학 조성물 및 치료 방법 |
-
2017
- 2017-12-15 WO PCT/CN2017/116413 patent/WO2018108147A1/zh unknown
- 2017-12-15 RU RU2019121794A patent/RU2731535C1/ru active
- 2017-12-15 DK DK17881171.7T patent/DK3527210T3/da active
- 2017-12-15 PT PT178811717T patent/PT3527210T/pt unknown
- 2017-12-15 CN CN201780076085.3A patent/CN110049765B/zh active Active
- 2017-12-15 AU AU2017376704A patent/AU2017376704B2/en active Active
- 2017-12-15 ES ES17881171T patent/ES2884064T3/es active Active
- 2017-12-15 EP EP17881171.7A patent/EP3527210B1/en active Active
- 2017-12-15 JP JP2019529888A patent/JP7048106B2/ja active Active
- 2017-12-15 KR KR1020197016757A patent/KR102368555B1/ko active IP Right Grant
- 2017-12-15 CA CA3046869A patent/CA3046869C/en active Active
- 2017-12-15 US US16/468,385 patent/US10933059B2/en active Active
- 2017-12-15 KR KR1020227006155A patent/KR20220028178A/ko not_active Application Discontinuation
- 2017-12-15 PL PL17881171T patent/PL3527210T3/pl unknown
- 2017-12-15 BR BR112019010559-0A patent/BR112019010559B1/pt active IP Right Grant
-
2019
- 2019-06-25 ZA ZA2019/04328A patent/ZA201904328B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3527210T3 (pl) | 2021-11-29 |
| EP3527210A4 (en) | 2019-11-20 |
| AU2017376704B2 (en) | 2021-08-05 |
| BR112019010559A2 (pt) | 2019-12-03 |
| RU2731535C1 (ru) | 2020-09-04 |
| CA3046869C (en) | 2022-05-17 |
| BR112019010559B1 (pt) | 2024-01-30 |
| JP2020510620A (ja) | 2020-04-09 |
| EP3527210B1 (en) | 2021-06-09 |
| ZA201904328B (en) | 2020-12-23 |
| US20190328722A1 (en) | 2019-10-31 |
| KR102368555B1 (ko) | 2022-02-28 |
| ES2884064T3 (es) | 2021-12-10 |
| CA3046869A1 (en) | 2018-06-21 |
| CN110049765A (zh) | 2019-07-23 |
| NZ753549A (en) | 2021-10-29 |
| EP3527210A1 (en) | 2019-08-21 |
| WO2018108147A1 (zh) | 2018-06-21 |
| AU2017376704A1 (en) | 2019-06-13 |
| DK3527210T3 (da) | 2021-08-09 |
| CN110049765B (zh) | 2022-02-01 |
| US10933059B2 (en) | 2021-03-02 |
| KR20190097007A (ko) | 2019-08-20 |
| JP7048106B2 (ja) | 2022-04-05 |
| KR20220028178A (ko) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258288B (en) | Hair strengthening compound and hair strengthening method | |
| IL251215B (en) | Cannabinoid preparation and method for treating pain | |
| SG11202003790PA (en) | Composition and method | |
| ZA201900689B (en) | New composition and process | |
| IL271728A (en) | Materials, uses and treatment methods | |
| EP3352729A4 (en) | METHODS AND COMPOSITIONS FOR TREATING SKIN | |
| EP3636281C0 (en) | METHOD FOR TREATING DEPRESSION AND PHARMACEUTICAL COMPOSITION | |
| GB201520255D0 (en) | Composition and method | |
| GB2564511B (en) | Composition, method and use | |
| GB201805016D0 (en) | Composition, method and use | |
| GB201705124D0 (en) | Composition, method and use | |
| GB201700116D0 (en) | Method and composition | |
| GB2539474B (en) | Glove and treatment method | |
| ZA201904328B (en) | Composition, application thereof and treatment method | |
| GB201509420D0 (en) | Composition and method | |
| ZA201904626B (en) | Cancer treatment method and composition | |
| ZA201904187B (en) | Method and composition | |
| HK1256689A1 (zh) | 含氧化劑組合物及其使用方法 | |
| GB201513492D0 (en) | Method and composition | |
| GB201716557D0 (en) | Composition, methods and uses | |
| GB201714238D0 (en) | Composition and method | |
| ZA201708307B (en) | Improved herbicidal composition, method and use | |
| GB201701186D0 (en) | Method and treatment | |
| GB201709464D0 (en) | Process and composition | |
| GB201709996D0 (en) | Improved composition and process |